Skip to main content
Log in

Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine?

  • Short Communication
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Background

Static imaging of amino acids does not allow differentiation of low versus high grade brain tumours. It has been shown that dynamic imaging of the amino acid analogue 18F-fluoroethyltyrosine (FET) can achieve this goal. In many centres, 11C-methionine (MET) is used for tumour imaging, but no clinical studies on the use of dynamic scanning for grading have been performed.

Methods

Thirty-four patients with primary brain glioma and histopathological confirmation were retrospectively studied using 40 min dynamic MET–PET with 220 MBq 11C-methionine. In relation to histopathological grading, various metabolic indices and temporal parameters as documented by Poepperl et al. (JNM 2006;47:393–403) were analyzed.

Results

None of the evaluated static or temporal parameters allowed discrimination between high and low grade tumours. On average, low grade tumours showed washout after the initial uptake maximum, while both increases and decreases were seen for high grade tumours. Only the relative early versus late uptake ratio showed a trend towards significance (−0.16 ± 0.17 for low grade versus 0.01 ± 0.25 for high grade; p = 0.07).

Conclusion

Unlike FET–PET, the uptake characteristics of MET-PET do not allow classification of low and high grade tumours on an individual patient basis. Since literature data indicate that both tracers have a similar performance regarding biopsy location, tumour delineation, and detection of recurrence, FET–PET should be advocated over MET–PET as its uptake mechanism also allows noninvasive grading in glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Stupp R, Hegi ME, van den Bent MJ, et al. Changing paradigms–an update on the multidisciplinary management of malignant glioma. Oncologist 2006;11:165–80.

    Article  PubMed  CAS  Google Scholar 

  2. Riemann B, Papke K, Hoess N, et al. Noninvasive grading of untreated gliomas: a comparative study of MR imaging and 3-(iodine 123)-L-alpha-methyltyrosine SPECT. Radiology 2002;225:567–74.

    Article  PubMed  Google Scholar 

  3. Jacobs AH, Kracht LW, Gossmann A, et al. Imaging in neurooncology. NeuroRx 2005;2:333–47.

    Article  PubMed  Google Scholar 

  4. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001;42:432–45.

    PubMed  CAS  Google Scholar 

  5. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L. [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol 2006;27:1432–37.

    PubMed  CAS  Google Scholar 

  6. Weber WA, Dick S, Reidl G, et al. Correlation between postoperative 3-[(123)I]iodo-L-alpha-methyltyrosine uptake and survival in patients with gliomas. J Nucl Med 2001;42:1144–150.

    PubMed  CAS  Google Scholar 

  7. Popperl G, Kreth FW, Herms J, et al. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? J Nucl Med 2006;47:393–403.

    PubMed  Google Scholar 

  8. Weckesser M, Langen KJ, Rickert CH, et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours. Eur J Nucl Med Mol Imaging 2005;32:422–9.

    Article  PubMed  CAS  Google Scholar 

  9. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J 2002;21:580–9.

    Article  PubMed  CAS  Google Scholar 

  10. Stober B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R. Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F]fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 2006;33:932–9.

    Article  PubMed  Google Scholar 

  11. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999;40:205–12.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank the PET radiopharmacy staff for their competent aid. KVL is Senior Clinical Investigator of the Research Foundation—Flanders (Belgium) (FWO).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Koen Van Laere.

Additional information

The first two authors contributed equally to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moulin-Romsée, G., D’Hondt, E., de Groot, T. et al. Non-invasive grading of brain tumours using dynamic amino acid PET imaging : does it work for 11C-Methionine?. Eur J Nucl Med Mol Imaging 34, 2082–2087 (2007). https://doi.org/10.1007/s00259-007-0557-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-007-0557-4

Keywords

Navigation